Toggle Main Menu Toggle Search

Open Access padlockePrints

Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia

Lookup NU author(s): Dr Lisa Russell, Lisa Jones, Dr Amir EnshaeiORCiD, Dr Stefano Tonin, Sarra Ryan, Dr Jeyanthy Eswaran, Dr Sirintra Nakjang, Professor Anthony MoormanORCiD, Professor Christine Harrison FRCPath FMedSci



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic landscape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using multiple genomic approaches. Clinical and demographic features of CRLF2-r patients were characteristic of B-ALL. Patients with IGH-CRLF2 were older (14yrs v 4yrs, P<0.001), while the incidence of CRLF2-r among Down syndrome patients was high (50/161, 31%). CRLF2-r co-occurred with primary chromosomal rearrangements but the majority (111/161, 69%) had B-other ALL. Copy number alteration (CNA) profiles were similar to B-other ALL, although CRLF2-r patients harboured higher frequencies of IKZF1 (60/138, 43% v 77/1351, 24%) and BTG1 deletions (20/138, 15% v 3/1351, 1%). There were significant differences in CNA profiles between IGH-CRLF2 and P2RY8-CRLF2 patients: IKZF1 (25/35, 71% v 36/108, 33%, P<0.001), BTG1 (11/35, 31% v 10/108, 9%, P =0.004) and ADD3 deletions (9/19, 47% v 5/38, 13%, P =0.008). A novel gene fusion, USP9X-DDX3X, was discovered in 10/54 (19%) of patients. Pathway analysis of the mutational profile revealed novel involvement for focal adhesion. Although the functional relevance of many of these abnormalities are unknown, they likely activate additional pathways, which may represent novel therapeutic targets.

Publication metadata

Author(s): Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ

Publication type: Article

Publication status: Published

Journal: Genes, Chromosomes & Cancer

Year: 2016

Volume: 56

Issue: 5

Pages: 363-372

Print publication date: 01/05/2017

Online publication date: 29/12/2016

Acceptance date: 25/12/2016

Date deposited: 27/02/2017

ISSN (print): 1045-2257

ISSN (electronic): 1098-2264

Publisher: John Wiley & Sons


DOI: 10.1002/gcc.22439

PubMed id: 28033648


Altmetrics provided by Altmetric


Funder referenceFunder name
15036Bloodwise (Formerly Leukaemia and Lymphoma Research) Closed Competition